Holen Sie sich die Stockscreener-App
0.2675
4.25%
0.0109
Vorhandelsmarkt:
.28
0.0125
+4.67%
Schlusskurs vom Vortag:
$0.2566
Offen:
$0.2575
24-Stunden-Volumen:
590.82K
Relative Volume:
1.07
Marktkapitalisierung:
$27.92M
Einnahmen:
$1.27M
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-5.1245
EPS:
-0.0522
Netto-Cashflow:
$-5.28M
1W Leistung:
+9.14%
1M Leistung:
-1.65%
6M Leistung:
+1.71%
1J Leistung:
-21.21%
1-Tages-Spanne:
$0.2521
$0.2724
1-Wochen-Bereich:
$0.2426
$0.2724
52-Wochen-Spanne:
$0.235
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Firmenname
IGC Pharma Inc
Sektor
Branche
Telefon
301-983-0998
Adresse
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2675 | 27.45M | 1.27M | -7.12M | -5.28M | -0.0522 |
VRTX
Vertex Pharmaceuticals Inc
|
523.91 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.05 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
866.11 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.97 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.00 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
IGC|IGC Pharma Inc|Price:0.266|Chg%:+0.002 - TradingKey
IGC Pharma Inc (IGC) Cash Flow - TradingKey
IGC Pharma Inc (IGC) Balance Sheet - TradingKey
IGC Pharma Inc (IGC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IGC Pharma Inc (IGC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IGC Pharma Inc (IGC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IGC Pharma, Inc. Revenue Breakdown – SWB:IGS1 - TradingView
IGC Pharma, Inc. Revenue Breakdown – LS:A1T87A - TradingView
IGC Pharma Inc (IGC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IGC Pharma Inc (IGC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IGC Pharma Inc (IGS1.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Enterprise value to revenue forward of IGC Pharma, Inc. – SWB:IGS1 - TradingView
Price to earnings forward of IGC Pharma, Inc. – SWB:IGS1 - TradingView
IGC Pharma Q1 2026 Earnings: Narrower Loss Meets Improved Efficiency Amid Market SlumpEPS Surprise History - dars.gov.et
IGC Pharma (NYSE: IGC) maps $3B–$10B Alzheimer’s agitation market in new deck - Stock Titan
IGC Pharma furnishes updated investor presentation, details CALMA Phase 2 progress and interim data - TradingView
The 6 Best Stocks Under 50 Cents To Buy This Year - The Stock Dork
IGC Pharma (NYSE: IGC) Showcasing 7 AI Breakthroughs Advancing Alzheimer’s Drug Discovery at AAIC 2026 - Barchart.com
IGC Pharma Showcases AI Portfolio at AAIC 2026 - ACCESS Newswire
Enterprise value to revenue forward of IGC Pharma, Inc. – FWB:IGS1 - TradingView
Price to earnings forward of IGC Pharma, Inc. – FWB:IGS1 - TradingView
IGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer’s Drug Development and Key 2026 Catalysts on The Street Podcast - Nonstop Local News
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow - Black Hills Pioneer
IGC Pharma puts AI tools on display for Alzheimer’s research in London - Stock Titan
IGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer's Drug - openPR.com
FinancialContentIGC Pharma (NYSE: IGC) CEO Discusses AI, Alzheimer’s Drug Development and Key 2026 Catalysts on The Street Podcast - FinancialContent
IGC Pharma (NYSE: IGC) CEO discusses AI, Alzheimer's drug development and key 2026 catalysts on The Street podcast - MSN
IGC Pharma (IGC) Declines Near Key Support as Selling Pressure PersistsRetail Volume - dars.gov.et
IGC: CEO and CFO Acquire 4.27 Million Shares in Company Stock - GuruFocus
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company - BioSpace
IGC Pharma CEO, finance chief buy $1.15M of common stock - MSN
IGC Pharma Executives Convert Debt Into Equity Shares - TipRanks
Executives convert $1,154,210 owed into IGC (NYSE: IGC) stock - Stock Titan
IGC Pharma Converts $1.15M Insider Debt Into Equity at $0.27 in Private Issuance - TradingView
IGCIGC Pharma Inc Revenue Breakdown - Finviz
IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares - marketscreener.com
Form 4 IGC Pharma Inc For: 1 July By Investing.com - Investing.com Nigeria
IGC Pharma (IGC) CEO converts $601K company debt into 2.23M shares - Stock Titan
Debt-for-equity swap gives IGC Pharma (IGC) PFO 2.0M new shares - Stock Titan
Stocks Under $1: TNMG, SRFM, PRSO, KNDI, IGC Offer Multibagger Potential as AI Boom Accelerates - openPR.com
MultiBagger MicroCaps IGC, RCT, PBK, HUMA, PRSO Stocks to Watch Now - openPR.com
IGC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock UptickLow Estimate Range - dars.gov.et
Enterprise value to revenue forward of IGC Pharma, Inc. – TRADEGATE:IGS1 - TradingView
IGC Pharma, Inc. Actuals & Estimates (AMEX:IGC) - TradingView
IGC Pharma, Inc. Actuals & Estimates (SWB:IGS1) - TradingView
Enterprise value to EBITDA forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
Enterprise value to EBITDA forward of IGC Pharma, Inc. – TRADEGATE:IGS1 - TradingView
IGC Pharma, Inc. Actuals & Estimates (DUS:IGS1) - TradingView
Enterprise value to EBIT forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
IGC Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of IGC Pharma, Inc. – TRADEGATE:IGS1 - TradingView
Finanzdaten der IGC Pharma Inc-Aktie (IGC)
Umsatz
Nettogewinn
Free Cashflow
ENV
IGC Pharma Inc-Aktie (IGC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mukunda Ram | CEO |
Apr 01 '26 |
Option Exercise |
0.13 |
656,410 |
84,000 |
4,649,088 |
| Mukunda Ram | CEO |
Apr 01 '26 |
Option Exercise |
0.00 |
49,999 |
0 |
910,751 |
| Moran James P | Director |
Apr 01 '26 |
Option Exercise |
0.00 |
130,000 |
0 |
1,235,735 |
| GRIMALDI CLAUDIA | PFO |
Apr 01 '26 |
Option Exercise |
0.15 |
238,462 |
36,000 |
1,372,714 |
| Mukunda Ram | CEO |
Feb 03 '26 |
Option Exercise |
0.00 |
50,000 |
0 |
860,752 |
| PRINS RICHARD K | Director |
Jan 19 '26 |
Option Exercise |
0.00 |
100,000 |
0 |
1,371,251 |
0.82%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):